Navigation Links
Targanta Submits Oritavancin New Drug Application
Date:2/11/2008

es in treating resistant bacterial infections, particularly those caused by MRSA. With Phase 3 trial results showing efficacy in only 3 to 7 days of treatment, we believe oritavancin may become part of a new treatment paradigm for infections caused by MRSA and other gram-positive bacteria, and could confer pharmacoeconomic benefits, if approved."

"Despite the introduction of several new antibiotics in the past decade, we continue to see an increase in the development of resistant gram-positive bacteria," said Peter Appelbaum, M.D., Ph.D., professor, division of clinical pathology and medical director, clinical microbiology at Penn State University. "There is an ongoing need for new bactericidal antibiotics that address the limitations of currently marketed therapies. Oritavancin has proven to be very potent in vitro against a broad spectrum of gram-positive organisms resistant to other agents. Also, due to its multiple mechanisms of action, oritavancin may hinder the rapid development of resistance; concordantly, contemporary surveillance studies have shown that oritavancin retains potency against all gram-positive organisms tested. The infectious disease community looks forward to adding a therapy with the characteristics of oritavancin."

More Background on the Market for Novel Antibiotics

There is a growing need for novel antibiotics since bacteria can mutate quickly and often develop resistance to existing antibiotics. Hospital-acquired infections are particularly likely to be resistant to existing antibiotics, but resistance is also growing rapidly in community- acquired infections. As bacteria become more resistant to currently marketed antibiotics, an increasing prevalence of drug-resistant bacterial pathogens can lead to increased mortality rates, prolonged hospitalizations, and increased healthcare costs.

About Targanta Therapeutics

Targanta Therapeutics Corporation is a biopharmaceutical company focused on developing and c
'/>"/>

SOURCE Targanta Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Targanta to Present at Lazard Capital Markets Fourth Annual Healthcare Conference
2. Targanta to Present at 9th Annual Mass Opportunities Investment Conference
3. Targanta Therapeutics Announces Pricing of its Initial Public Offering
4. Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting
5. MedImmune Submits Biologics License Application to FDA for Motavizumab
6. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
7. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
8. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
9. Cephalon Submits Supplemental New Drug Application for FENTORA
10. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
11. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015 ... "Antibody Production Market by Product (Equipment, Consumables), by Type ... Companies, Diagnostic Labs, Research Institutes) - Analysis & ... report studies the global Antibody Production Market for ... market is expected to reach $2.572 Billion by ...
(Date:4/30/2015)... May 01, 2015 Spirax Sarco, the ... extremely proud to announce that for the first time ... a winner of a Queen’s Award for Innovation – ... design and manufacture of a unique flowmeter. , The ... alternative to traditional steam flow measurement. The device ...
(Date:4/30/2015)... DIEGO , April 30, 2015   Tamir ... announced today an update on its Ebola antiviral therapy ... Tamir,s leading candidates, TMR004, is currently being evaluated and ... of the battle against Ebola. During the first quarter ... And Leadership Meeting To Accelerate The Evaluation of Potential ...
(Date:4/30/2015)... 30, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... that it has commenced an underwritten public offering of ... the underwriters a 30-day option to purchase up to ... stock offered in the public offering. The offering is ... assurance as to whether or when the offering may ...
Breaking Biology Technology:Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3
... Md., Sept. 23 Arisyn Therapeutics Inc.,(Arisyn) announced ... UAF,Technologies and Research, L.L.C. (UTR) a series of ... efficacy spectrum,against a variety of infectious organisms and ... assume the intellectual property portfolio. In,return, UTR will ...
... The National Women,s Health Resource Center,s Breast Cancer Study ... the #1 Risk Factor for Breast Cancer, RED ... study by,the not-for-profit National Women,s Health Resource Center (NWHRC), ... are,dissatisfied with their overall physical appearance are significantly less,likely ...
... Environmental,Tectonics Corporation,s (Amex: ETC ) ("ETC" or ... placement of two BARA-MED(R) XD,Monoplace Hyperbaric Chambers at ... in Corpus Christi, Texas, in 1905 and is,the ... the region. The,facility offers South Texans a full ...
Cached Biology Technology:Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer 2Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer 3Video: Women Unsatisfied With Body and Breasts, Less Likely to Comply With Screenings, Including Mammography 2Video: Women Unsatisfied With Body and Breasts, Less Likely to Comply With Screenings, Including Mammography 3Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers 2Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers 3
(Date:3/30/2015)... , Mar. 26, 2015 Research and Markets ... the "Global Gesture Recognition Market in Automotive Sector ... analysts forecast the Global Gesture Recognition market in Automotive ... the period 2013-2018. Gesture recognition is the ... different gestures of an individual. Gesture recognition technology can ...
(Date:3/24/2015)... BEACH GARDENS, Fla. , March 24, 2015 ... biometric identity management solutions, today announced that its ... premium clothing accessory retailer Goorin Bros . ... The Crossmatch biometrics-based solution secures access to the ... from the increased risk of data breaches. ...
(Date:3/20/2015)... Mar. 20, 2015 Research and Markets ... of the "India Sensors Market Forecast and ... The sensor market is projected to grow ... Consumer electronics, automotive, industrial and healthcare sectors ... the country. In addition, adoption of MEMS technology ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... National Heart, Lung, and Blood Institute (NHLBI) of the ... guidelines in the United States for the diagnosis and ... inherited bleeding disorder. The guidelines include recommendations on screening, ... extensive article on the guidelines is published online Feb. ...
... -- Teens who can recognize and resist the persuasive ... succumb to alcohol advertising and peer pressure to drink. ... middle school students by Weill Cornell Medical College researchers ... edition). Previous research has shown the connection between advertising ...
... has released a report that identifies the potential volume ... acres of Arizona forests, representing the first major agreement ... forest thinning. The Wood Supply Analysis report identifies ... feet of wood and 8 million tons of biomass ...
Cached Biology News:NHLBI issues first US von Willebrand Disease clinical practice guidelines 2NHLBI issues first US von Willebrand Disease clinical practice guidelines 3NHLBI issues first US von Willebrand Disease clinical practice guidelines 4Learning how to say 'no' to alcohol advertising and peer pressure works for inner-city adolescents 2Stakeholders use science to find common ground on wood supply from forests 2Stakeholders use science to find common ground on wood supply from forests 3
SHP-2 Antibody...
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
Mouse monoclonal [RIZ1723] to PRDM2/RIZ...
MagSi uniform silica particles coated with a carboxyl group containing polymer, covalently attached to the bead surface....
Biology Products: